Literature DB >> 7057253

Enterohepatic circulation in man of a gamma-emitting bile-acid conjugate, 23-selena-25-homotaurocholic acid (SeHCAT).

M V Merrick, M A Eastwood, J R Anderson, H M Ross.   

Abstract

A conjugated bile acid, 23-selena-25-homotaurocholic acid (SeHCAT), labeled with the gamma emitter Se-75, has been evaluated in man. Absorption and excretion were compared with that of simultaneously administered [23-14C]cholic acid. SeHCAT is absorbed quantitatively following oral administration, secreted into the bile at the same rate as cholic acid, reabsorbed from the small intestine, and resecreted. It is not absorbed when the terminal ileum has been excised or bypassed. SeHCAT is therefore the first of a new class of radiopharmaceuticals, namely, gamma-emitting tracers of the complete cycle of the enterohepatic circulation. Its use will simplify investigation of the functional state of the terminal ileum by eliminating the need to collect and process feces.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7057253

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


  23 in total

1.  Ileal absorption of bile acids in patients with chronic cholestasis: SeHCAT test results and effect of ursodeoxycholic acid (UDCA).

Authors:  O Chazouillères; P Marteau; M Haniche; R Jian; R Poupon
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

2.  Scintigraphic evaluation of enterogastric reflux using 75Se-HCAT: methodology and first clinical observations.

Authors:  A Furno; G Sciarretta; G Fagioli; R Pozzato; P Malaguti
Journal:  Eur J Nucl Med       Date:  1987

Review 3.  Recycling rate of bile acids in the enterohepatic recirculation as a major determinant of whole body 75SeHCAT retention.

Authors:  A Michael Peters; Julian R F Walters
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-06-06       Impact factor: 9.236

4.  Bile acid malabsorption in Crohn's disease and indications for its assessment using SeHCAT.

Authors:  H Nyhlin; M V Merrick; M A Eastwood
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

5.  Intestinal absorption of the bile acid analogue 75Se-homocholic acid-taurine is increased in primary biliary cirrhosis, and reverts to normal during ursodeoxycholic acid administration.

Authors:  A Lanzini; M G De Tavonatti; B Panarotto; S Scalia; A Mora; F Benini; O Baisini; F Lanzarotto
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

6.  Design and characterization of a novel fluorinated magnetic resonance imaging agent for functional analysis of bile Acid transporter activity.

Authors:  Diana Vivian; Kunrong Cheng; Sandeep Khurana; Su Xu; Valerie Whiterock; Drew Witter; Kimberley A Lentz; Kenneth S Santone; Jean-Pierre Raufman; James E Polli
Journal:  Pharm Res       Date:  2013-01-15       Impact factor: 4.200

7.  Gall-bladder and colonic retention of SeHCAT: a re-evaluation.

Authors:  M V Merrick
Journal:  Eur J Nucl Med       Date:  1994-09

8.  Bile acid malabsorption as a cause of chronic diarrhea: diagnostic value of 7alpha-hydroxy-4-cholesten-3-one in serum.

Authors:  G H Sauter; W Münzing; C von Ritter; G Paumgartner
Journal:  Dig Dis Sci       Date:  1999-01       Impact factor: 3.199

9.  75Se HCAT test in the detection of bile acid malabsorption in functional diarrhoea and its correlation with small bowel transit.

Authors:  G Sciarretta; G Fagioli; A Furno; G Vicini; L Cecchetti; B Grigolo; A Verri; P Malaguti
Journal:  Gut       Date:  1987-08       Impact factor: 23.059

10.  Measurement of bile acid half-life using [75Se]HCAT in health and intestinal diseases. Comparison with [75Se]HCAT abdominal retention methods.

Authors:  R Ferraris; G Galatola; A Barlotta; R Pellerito; M Fracchia; F Cottino; M de la Pierre
Journal:  Dig Dis Sci       Date:  1992-02       Impact factor: 3.199
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.